
News|Videos|June 25, 2026
Pharma Fundamentals: Biologics Development and PDA’s Technical Report No. 56
This episode of Pharma Fundamentals explains the difference between a quality system for biologics compared with small-molecule drugs and the Parenteral Drug Association’s revision to Technical Report No. 56.
Advertisement
Advertisement
In this episode of PharmTech’s Pharma Fundamentals, Susan Schniepp, distinguished fellow with Nelson Labs and a member of PharmTech's editorial advisory board, and Amnon Eylath, president and founder of Broad Spectrum GXP, discuss biologics development, the quality system, and the Parenteral Drug Association's (PDA) revision to Technical Report No. 56 (TR56),1 which Eylath is a co-author on.
Related to this article

The FDA grants accelerated approval to neladalkib for pretreated ALK-positive lung cancer, showing how next-gen kinase inhibitors tackle drug resistance

Robert Sciscento, a senior scientist at Alcami Corporation, discusses scaling up oral peptide products and what the future looks like for GLP-1 drug delivery.

Robert Sciscento, a senior scientist at Alcami Corporation, discusses formulation and delivery systems for oral peptides that might fix bioavailability challenges.

The FDA approves oral SERD giredestrant for ESR1-mutated breast cancer after a 62% risk cut, tying supply to testing ahead of a November 30, 2026 adjuvant decision.

Cole and Jaenisch explain where pharma should keep manual checks, how to vet AI skills in hires, and why self-taught AI risks GMP.

The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.

Proposal for the Public Procurement Act, adoption of a new pharmaceutical legislation, and revision of pharmacovigilance practices should improve patient access to safe and innovative medicines in Europe.
Advertisement
Advertisement

